Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nicholas Summers, Jacqueline Vanderpuye-Orgle, Marcia Reinhart, Meghan Gallagher & Oliver Sartor. (2017) Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Current Medical Research and Opinion 33:11, pages 1995-2008.
Read now
Read now
Sunil Parimi & Jenny J. Ko. (2017) Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. Expert Review of Anticancer Therapy 17:10, pages 939-949.
Read now
Read now
Chiara Ciccarese, Elisabetta Nobili, Donatella Grilli, Laura Casolari, Karim Rihawi, Francesco Gelsomino, Giampaolo Tortora & Francesco Massari. (2016) The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Review of Anticancer Therapy 16:7, pages 681-696.
Read now
Read now
Alejo Rodriguez-Vida, Myria Galazi, Sarah Rudman, Simon Chowdhury & Cora N Sternberg. (2015) Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy 9, pages 3325-3339.
Read now
Read now
Edoardo Francini, Roberto Petrioli & Giandomenico Roviello. (2014) No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Review of Anticancer Therapy 14:10, pages 1135-1140.
Read now
Read now
Articles from other publishers (50)
Michaela C. Barbier, Yuki Tomonaga, Dominik Menges, Henock G. Yebyo, Sarah R. Haile, Milo A. Puhan & Matthias Schwenkglenks. (2022) Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLOS ONE 17:11, pages e0277282.
Crossref
Crossref
Alicia K. Morgans, Thomas Hutson, Alice Kai Dan Guan, David Garcia, Anna Zhou, Edward Drea & Nicholas J. Vogelzang. (2022) An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. BMC Health Services Research 22:1.
Crossref
Crossref
Chirag Desai, Ashok K. Vaid, Ghanashyam Biswas, Sandeep Batra, Palanki S. Dattatreya, Prabrajya Narayan Mohapatra, Deepak Dabkara, Adwaita Gore, Sagar B. Bhagat, Saiprasad Patil & Hanmant Barkate. (2022) Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. Oncology and Therapy 10:1, pages 143-165.
Crossref
Crossref
Ming-kun Chen, Zhi-jian Liang, Dao-Sheng Luo, Kang-yi Xue, De-ying Liao, Zheshen Li, Yuzhong Yu, Zhe-Sheng Chen & Shan-Chao Zhao. (2022) Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. Frontiers in Pharmacology 13.
Crossref
Crossref
Stefan A.J. Buck, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ronald de Wit & Robert J. van Soest. (2021) Cross-resistance and drug sequence in prostate cancer. Drug Resistance Updates 56, pages 100761.
Crossref
Crossref
Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Vaz, Gabriele Cruciani & Isaac Yi Kim. (2021) Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 20:3, pages 490-499.
Crossref
Crossref
J. Cassinello, T. Domínguez-Lubillo, M. Gómez-Barrera, T. Hernando, R. Parra, I. Asensio, M.A. Casado & P. Moreno. (2021) Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. Cancer Treatment Reviews 93, pages 102152.
Crossref
Crossref
Yushi Naito, Masashi Kato, Hideji Kawanishi, Yuri Yuguchi, Takuma Yuba, Tomohiro Ishikawa, Kyosuke Hattori, Akiyuki Yamamoto, Tomoyasu Sano, Yoshihisa Matsukawa, Toru Kimura, Toshinori Nishikimi, Ryohei Hattori, Toyonori Tsuzuki & Momokazu Gotoh. (2020) The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study. The Prostate 80:15, pages 1373-1380.
Crossref
Crossref
Orazio Caffo, Michel Wissing, Diletta Bianchini, Andries Bergman, Frederik B. Thomsen, Sebastian Schmid, Evan Y. Yu, Evangelos Bournakis, Avishay Sella, Vittorina Zagonel, Ugo De Giorgi, Marcello Tucci, Hans Gelderblom, Luca Galli, Giovanni Pappagallo, Emilio Bria, Isabella Sperduti & Stephane Oudard. (2020) Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 18:1, pages 69-76.e4.
Crossref
Crossref
Doo Yong Chung, Dong Hyuk Kang, Jong Won Kim, Do Kyung Kim, Joo Yong Lee, Chang Hee Hong & Kang Su Cho. (2019) Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers 12:1, pages 8.
Crossref
Crossref
Kazumasa Komura, Yuya Fujiwara, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Tomohisa Matsunaga, Atsushi Ichihashi, Takeshi Tsutsumi, Takuya Tsujino, Yuki Yoshikawa, Yudai Nishimoto, Tomoaki Takai, Koichiro Minami, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Kiyoshi Takahara, Teruo Inamoto & Haruhito Azuma. (2019) Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. Journal of Clinical Medicine 8:8, pages 1251.
Crossref
Crossref
Hamid Emamekhoo, Pedro C. Barata, Natasha C. Edwin, Kaitlin M. Woo, Petros Grivas & Jorge A. Garcia. (2018) Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer 16:6, pages 429-436.
Crossref
Crossref
Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliott, Enrique Grande, Amal Melhem-Bertrandt, Benoit Baron, Mohammad Hirmand, Patrick Werbrouck & Karim Fizazi. (2018) Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. European Urology 74:1, pages 37-45.
Crossref
Crossref
Kazumasa Komura, Christopher J Sweeney, Teruo Inamoto, Naokazu Ibuki, Haruhito Azuma & Philip W Kantoff. (2018) Current treatment strategies for advanced prostate cancer. International Journal of Urology 25:3, pages 220-231.
Crossref
Crossref
Orazio Caffo, Antonello Veccia, Stefania Kinspergher & Francesca Maines. (2018) Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. Future Oncology 14:5, pages 431-442.
Crossref
Crossref
Nicole Melong, Shelby Steele, Morgan MacDonald, Alice Holly, Colin C. Collins, Amina Zoubeidi, Jason N. Berman & Graham Dellaire. (2017) Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Scientific Reports 7:1.
Crossref
Crossref
Michiel H.F. Poorthuis, Robin W.M. Vernooij, R. Jeroen. A. van Moorselaar & Theo M. de Reijke. (2017) Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. Seminars in Oncology 44:5, pages 358-371.
Crossref
Crossref
Dimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, Richard Cathomas, Silke Gillessen, Christian Rothermundt, Loretta Hasler, Ralph Winterhalder, Andreas Barth, Walter Mingrone, Catrina Uhlmann Nussbaum, Lukas von Rohr, Philippe von Burg, Mathias Schmid, Jürg Richner, Sylvia Baumann, Reto Kühne, Frank Stenner & Sacha I. Rothschild. (2017) Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. Clinical Genitourinary Cancer 15:3, pages e315-e323.
Crossref
Crossref
Emmanuel S. Antonarakis, Chandtip Chandhasin, Erica Osbourne, Jun Luo, Marianne D. Sadar & Frank Perabo. (2016) Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. The Oncologist 21:12, pages 1427-1435.
Crossref
Crossref
Yoko Yamada, Nobuaki Matsubara, Ken-ichi Tabata, Takefumi Satoh, Naoto Kamiya, Hiroyoshi Suzuki, Takashi Kawahara, Hiroji Uemura, Akihiro Yano & Satoru Kawakami. (2016) Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. BMC Research Notes 9:1.
Crossref
Crossref
Stéphane Oudard, Pablo Maroto, Gaston Demonty & Winald R. Gerritsen. (2016) Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?. European Urology Focus 2:4, pages 426-440.
Crossref
Crossref
Giulia Baciarello & Cora N. Sternberg. (2016) Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. Critical Reviews in Oncology/Hematology 106, pages 14-24.
Crossref
Crossref
Jonathan Hung, Andrew R. Taylor, George W. Divine, Jason M. Hafron & Clara Hwang. (2016) The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Clinical Genitourinary Cancer 14:5, pages 381-388.
Crossref
Crossref
Mallika Dhawan & Charles J. Ryan. (2016) Utility of novel androgen receptor therapies in the real world: A nuanced approach. Urologic Oncology: Seminars and Original Investigations 34:8, pages 340-347.
Crossref
Crossref
Thomas Seisen, Morgan Rouprêt, Florie Gomez, Gabriel G. Malouf, Shahrokh F. Shariat, Benoit Peyronnet, Jean-Philippe Spano, Géraldine Cancel-Tassin & Olivier Cussenot. (2016) A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. Cancer Treatment Reviews 48, pages 25-33.
Crossref
Crossref
Souhil Lebdai, Victor Basset, Julien Branchereau, Alexandre de La Taille, Vincent Flamand, Thierry Lebret, Thibaut Murez, Yann Neuzillet, Guillaume Ploussard & François Audenet. (2015) What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. World Journal of Urology 34:5, pages 617-624.
Crossref
Crossref
Zafeiris Zafeiriou, Anuradha Jayaram, Adam Sharp & Johann S. de Bono. (2016) Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Drugs 76:4, pages 421-430.
Crossref
Crossref
Naohiro Fujimoto. (2016) Novel agents for castration-resistant prostate cancer: Early experience and beyond. International Journal of Urology 23:2, pages 114-121.
Crossref
Crossref
Jack Schalken & John M. Fitzpatrick. (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU International 117:2, pages 215-225.
Crossref
Crossref
Sushil K. Badrising, Vincent van der Noort, Paul Hamberg, Jules L.L.M. Coenen, Maureen J. Aarts, Inge M. van Oort, Alfons J.M. van den Eertwegh, Maartje Los, H. Pieter van den Berg, Hans Gelderblom, Suzan Vrijaldenhoven, Emile D. Kerver, Theo van Voorthuizen, Igle J. de Jong, John B. Haanen & Andries M. Bergman. (2016) Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology 91:5, pages 267-273.
Crossref
Crossref
Tian Zhang & Andrew J. Armstrong. (2015) Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Current Oncology Reports 18:1.
Crossref
Crossref
Zafeiris Zafeiriou, Niven Mehra & Johann S. de Bono. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
125
155
.
Sushil K. Badrising, Vincent van der Noort, Alfons J.M. van den Eertwegh, Paul Hamberg, Inge M. van Oort, Hendrik P. van den Berg, Maartje Los, Maureen J.B. Aarts, Jules L.L.M. Coenen, Hans Gelderblom, Igle J. de Jong, Emile D. Kerver, Suzan Vrijaldenhoven, Theo van Voorthuizen, Fabienne Warmerdam, John B. Haanen & Andries M. Bergman. (2016) Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. The Prostate 76:1, pages 32-40.
Crossref
Crossref
E. David Crawford, Celestia S. Higano, Neal D. Shore, Maha Hussain & Daniel P. Petrylak. (2015) Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Journal of Urology 194:6, pages 1537-1547.
Crossref
Crossref
Francesca Maines, Orazio Caffo, Antonello Veccia, Chiara Trentin, Giampaolo Tortora, Enzo Galligioni & Emilio Bria. (2015) Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology 96:3, pages 498-506.
Crossref
Crossref
K. Chi, S.J. Hotte, A.M. Joshua, S. North, A.W. Wyatt, L.L. Collins & F. Saad. (2015) Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Annals of Oncology 26:10, pages 2044-2056.
Crossref
Crossref
Klaus Brasso, Frederik B. Thomsen, Andres J. Schrader, Sebastian C. Schmid, David Lorente, Margitta Retz, Axel S. Merseburger, Christoph A. von Klot, Martin Boegemann & Johann de Bono. (2015) Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. European Urology 68:2, pages 317-324.
Crossref
Crossref
Tian Zhang, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin & Andrew J. Armstrong. (2015) Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 13:4, pages 392-399.
Crossref
Crossref
Guru Sonpavde, Christopher G. Wang, Matthew D. Galsky, William K. Oh & Andrew J. Armstrong. (2015) Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). BJU International 116:1, pages 17-29.
Crossref
Crossref
Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame, Enrico Campadelli, Giovanni Lo Re, Giuseppe Procopio, Roberto Sabbatini, Maddalena Donini, Franco Morelli, Donata Sartori, Paolo Zucali, Francesco Carrozza, Alessandro D’Angelo, Giovanni Vicario, Francesco Massari, Daniele Santini, Teodoro Sava, Caterina Messina, Giuseppe Fornarini, Leonardo La Torre, Riccardo Ricotta, Michele Aieta, Claudia Mucciarini, Fable Zustovich, Sveva Macrini, Salvatore Luca Burgio, Sandra Santarossa, Carmine D’Aniello, Umberto Basso, Sara Tarasconi, Enrico Cortesi, Consuelo Buttigliero, Fiorella Ruatta, Antonello Veccia, Vincenza Conteduca, Francesca Maines & Enzo Galligioni. (2015) Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology 68:1, pages 147-153.
Crossref
Crossref
Anthony M. Joshua, Neal D. Shore, Fred Saad, Kim N. Chi, Carl A. Olsson, Urban Emmenegger, Mark Scholz, William Berry, Som D. Mukherjee, Eric Winquist, Naomi B. Haas, Margaret A. Foley, Carl Dmuchowski, Frank Perabo, Mohammad Hirmand, Nahla Hasabou & Dana Rathkopf. (2015) Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America. The Prostate 75:8, pages 836-844.
Crossref
Crossref
Arun A. Azad, Stanislav V. Volik, Alexander W. Wyatt, Anne Haegert, Stephane Le Bihan, Robert H. Bell, Shawn A. Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov, Jack Youngren, Pamela Paris, George Thomas, Eric J. Small, Yuzhuo Wang, Martin E. Gleave, Colin C. Collins & Kim N. Chi. (2015) Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research 21:10, pages 2315-2324.
Crossref
Crossref
Loana B. Valenca, Christopher J. Sweeney & Mark M. Pomerantz. (2015) Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treatment Reviews 41:4, pages 332-340.
Crossref
Crossref
Gillian M. Keating. (2015) Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Drugs & Aging 32:3, pages 243-249.
Crossref
Crossref
Axel S. Merseburger, Gabriel P. Haas & Christoph-A. von Klot. (2014) An update on enzalutamide in the treatment of prostate cancer. Therapeutic Advances in Urology 7:1, pages 9-21.
Crossref
Crossref
Won Kim & Charles J. Ryan. (2015) Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer 121:3, pages 361-371.
Crossref
Crossref
Arun A. Azad, Bernhard J. Eigl, R. Nevin Murray, Christian Kollmannsberger & Kim N. Chi. (2015) Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients. European Urology 67:1, pages 23-29.
Crossref
Crossref
Jeanny B. Aragon-Ching. (2014) The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. Frontiers in Oncology 4.
Crossref
Crossref
David Lorente, Diletta Bianchini, Alejo Rodriguez-Vida, Aurelius Omlin, Carmel Pezaro, Roberta Ferraldeschi, Andrea Zivi, Gerhardt Attard, Simon Chowdhury & Johann S. De Bono. (2014) Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. European Journal of Cancer 50:5, pages 1042-1043.
Crossref
Crossref
EvanY Yu & WilliamK Oh. (2014) The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian Journal of Andrology 16:3, pages 331.
Crossref
Crossref